Straits Times Index
3,237.02 +4.34 (+0.13%) S&P 500
4,704.54 +15.87 (+0.34%) Dow
35,870.95 -60.10 (-0.17%) Nasdaq
15,993.71 +72.14 (+0.45%) BTC-USD
57,625.62 +16.07 (+0.03%) CMC Crypto 200
1,402.14 -65.80 (-4.48%)
Gilead Sciences, Inc. (GILD)
| Previous close | 67.46 |
| Open | 67.54 |
| Bid | 68.05 x 1300 |
| Ask | 68.32 x 2900 |
| Day's range | 67.36 - 68.28 |
| 52-week range | 56.56 - 73.34 |
| Volume | |
| Avg. volume | 6,559,441 |
| Market cap | 85.021B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 282.46 |
| EPS (TTM) | 0.24 |
| Earnings date | 02 Feb 2022 - 07 Feb 2022 |
| Forward dividend & yield | 2.84 (3.96%) |
| Ex-dividend date | 14 Sep 2021 |
| 1y target est | 75.99 |
- Motley Fool
Why NRx Pharmaceuticals Stock Soared Today
Shares of NRx Pharmaceuticals (NASDAQ: NRXP) surged on Monday after the healthcare company released promising clinical trial data for its investigational COVID-19 treatment, aviptadil. An analysis conducted by respected statistician Dr. David Schoenfeld found that patients treated with aviptadil had a significantly higher probability of recovering from critical COVID-19 and respiratory failure than those who received existing therapies. Among those who previously received Gilead Sciences' (NASDAQ: GILD) remdesivir, patients treated with aviptadil were 2.5 times more likely to be alive and free of respiratory failure at 60 days than those who received a placebo.
- Business Wire
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
FOSTER CITY, Calif., November 29, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) will present additional data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10. These data reinforce the benefits of Trodelvy and the importance of Gilead’s transformative science in cancers with high unmet need. In the United States, Trodelvy is indicated for the treatment of adult patients with unresecta
- Zacks
Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.
